Topic: rheumatoid arthritis
Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety.
A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.
Evobrutinib cut gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say if it beat Tecfidera.
The past week ushered in news about a toxin in scorpion venom that may relieve RA and a skin bacterium with anti-cancer powers.
The setback leaves Lilly and partner Hanmi Pharmaceutical to weigh whether it is worth moving the Bruton's TKI forward in other indications.
AbbVie has scored another key trial win with its JAK1 inhibitor upadacitinib, but a death and pulmonary embolism take some of the shine off the data.
Galapagos has taken up its option to co-promote filgotinib with Gilead in certain European nations, but Gilead will be free to acquire its partner in two weeks.
The 18-month study will assess whether Vectra DA delivers better outcomes and lower costs than conventional approaches.
A University of Edinburgh-led team has uncovered a mechanism in MS that prevents regulatory T cells—which prevent autoimmune activity—from developing.
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.